evipedia.ai
← Back

Betaine for Health & Longevity

Evidence Review created on 09/11/2026 using AI4L / Opus 5

Also known as: Trimethylglycine, TMG, Glycine Betaine, Betaine Anhydrous, N,N,N-Trimethylglycine, Oxyneurine

Motivation

Betaine (also called trimethylglycine) is a small molecule concentrated in beets, wheat bran, spinach and shellfish, and made inside the body from choline. Its defining feature is that it carries three loosely held methyl groups that it can hand to other molecules, which is why it sits at the crossroads of liver fat handling, muscle performance and homocysteine control.

Sugar-beet refiners have produced betaine since the nineteenth century, first for livestock feed and later as an approved oral treatment for a rare inherited disorder of homocysteine metabolism. Ordinary diets supply roughly one to two grams a day; supplement doses run several times higher, and betaine has become a routine ingredient in sports formulas and longevity stacks. Attention widened further when research on exercise metabolism reported that betaine levels rise with repeated training and that giving it to aged animals reproduces part of what training does.

This review examines what human evidence shows about betaine for health and longevity: which effects are measured and replicated, which remain contested, what the dose-dependent trade-offs are, and how the compound is used, sourced and monitored in practice.

Benefits - Risks - Protocol - Conclusion

These sources give a high-level orientation to betaine’s biology, its clinical record, and the longevity claims now attached to it.

Four items are listed rather than five, because no fifth source met the bar without padding. Direct searches of hubermanlab.com, chriskresser.com and lifespan.io found no substantial betaine content: Lifespan.io returns nothing on betaine or trimethylglycine, and the other two sites carry only passing mentions inside articles on choline, methylation or pre-workout formulas. FoundMyFitness carries no article, episode or commentary on betaine: its seven publicly readable hits for the term are passing mentions inside choline and methyl-donor summaries, plus a title-only research stub that links straight out to a journal paper without discussing it, so nothing from that platform could be listed and annotated here.

Grokipedia

  • Betaine

    Broad reference entry covering betaine’s chemistry, its production from choline, its methyl-donor and cell-water-balancing roles, its approved medical use, and the 2025 exercise-mimetic findings in animals.

Examine

  • Betaine

    Graded summary of every human betaine trial, with dose ranges for homocysteine lowering, liver fat and resistance training, and an explicit note on the cholesterol rise at high doses.

ConsumerLab

No dedicated ConsumerLab article or product review for betaine exists. Betaine appears only inside broader entries covering testosterone-boosting supplements, heart-health supplements and acid reflux, and in short clinical updates that link back to those entries. None of these is the site’s primary, dedicated page for the compound.

Systematic Reviews

These are the systematic reviews and meta-analyses that define what betaine supplementation does and does not do in humans.

Mechanism of Action

Betaine acts through three routes.

The first is methyl donation. Betaine hands one of its three methyl groups to homocysteine — an amino acid that builds up when methylation traffic slows — via betaine-homocysteine S-methyltransferase (BHMT, the liver and kidney enzyme that runs this transfer), yielding methionine and dimethylglycine (DMG, betaine minus one methyl group). Methionine is recycled into S-adenosylmethionine (SAMe, the universal methyl carrier for hundreds of reactions, including the tags that switch genes on and off). This route parallels the folate-dependent one, so betaine can carry methylation when folate is scarce.

The second is osmolyte action: betaine concentrates in kidney, liver and muscle cells, balancing water pressure across the cell membrane and stabilizing proteins under stress — the proposed basis for its performance effects. A competing reading attributes that signal to blunted lactate accumulation rather than cell swelling, and notes that creatine already occupies the osmolyte route: adding betaine to creatine produced no extra benefit.

The third is direct binding: betaine attaches to and inhibits TBK1 (TANK-binding kinase 1, a signaling enzyme that drives inflammation and cellular aging) — the route proposed by the exercise-mimetic work, so far demonstrated only in animals.

Pharmacologically betaine is not receptor-selective, is absorbed within an hour, distributes to kidney, liver and muscle, and is cleared by metabolism rather than by the kidneys; its elimination half-life is near 14 hours after one dose and roughly 41 hours on repeated dosing. Cytochrome P450 enzymes (the liver’s main drug-processing family) do not metabolize it.

Historical Context & Evolution

Betaine was isolated from sugar-beet molasses in 1866 and named for the beet genus Beta. For a century its commercial life was agricultural: a feed additive that helped livestock tolerate heat and salt stress and shifted carcasses toward lean tissue.

Its medical career began with inherited errors of homocysteine metabolism. In cystathionine beta-synthase deficiency (CBS deficiency, an inherited fault in the enzyme that disposes of homocysteine), plasma homocysteine can exceed 200 micromoles per liter and young patients suffer strokes, clots and lens dislocation. High-dose oral betaine opened a second disposal route and lowered those concentrations, and the US regulator approved a prescription betaine anhydrous product for the condition in 1996.

That success fed a broader hypothesis: if homocysteine damages arteries, lowering it in ordinary adults should prevent heart attacks. Large trials of folic acid and B vitamins lowered homocysteine substantially without preventing heart attacks or deaths, and the pooled Cochrane analysis confirmed that, finding only a small reduction in stroke. Interest in homocysteine as a target cooled. The question was not closed, however: those trials tested vitamins rather than betaine, enrolled people with established disease, and ran against a folic-acid-fortified food supply. Betaine’s own trials, meanwhile, revealed a lipid cost the vitamin trials did not have. The 2025 exercise-mimetic work reopened the longevity case on entirely different mechanistic ground.

Expected Benefits

High 🟩 🟩 🟩

Increased Muscular Strength and Power

Betaine raises maximal strength, most consistently in the lower body, and improves vertical jump height. The proposed mechanism is cellular water regulation plus blunted lactate accumulation during high-volume work, though creatine occupies the same route. The evidence base is a 2024 meta-analysis of 17 placebo-controlled trials in 317 trained and untrained participants, supported by a separate crossover trial in CrossFit practitioners. Upper-body strength, sprint power and muscular endurance did not improve, and only about one participant in five across the pooled trials was female.

Magnitude: A pooled effect size of 0.47 for maximal strength, 0.49 for the lower body and 0.36 for vertical jump — small to moderate. In the individual trials, lower-body one-repetition maximum (1RM, the heaviest load that can be lifted once) typically rose by a few percent over placebo across two to six weeks of training.

Medium 🟩 🟩

Reduced Liver Fat and Liver-Injury Markers in Fatty Liver Disease ⚠️ Conflicted

In fatty liver disease unrelated to alcohol, betaine supplies the methyl groups needed to export fat from liver cells. A 12-month placebo-controlled trial in 55 patients found lower liver-fat grade on betaine but no change in disease activity score or fibrosis; its authors concluded it amounted to protection against worsening. Three later uncontrolled dose-ranging trials found alanine aminotransferase (ALT, the enzyme that leaks from injured liver cells) fell at 2–8 grams daily. Net reading: betaine shifts liver fat and injury markers without yet changing liver structure under controlled conditions.

Magnitude: In the controlled trial, liver-fat grade decreased on betaine while activity score and fibrosis stage were unchanged. In the uncontrolled trials the abnormal portion of ALT fell significantly at 2, 4 and 8 grams daily but not at 1 gram. Neither report states an effect size for the liver outcome, so the literature gives no outcome figure.

Low 🟩

Lower Plasma Homocysteine

Direct readout of betaine’s methyl-donation role. Pooled placebo-controlled trials show a consistent fall in plasma homocysteine at 4 grams daily or more, replicated independently. Graded Low because homocysteine is an indirect marker: lowering it with vitamins left heart attacks and deaths unchanged, cutting only stroke slightly.

Magnitude: A pooled reduction of about 1.2 to 1.3 micromoles per liter, roughly 5 to 20 percent from baseline, reached within six weeks and dose-dependent up to about 4 grams daily.

Reduced Body Fat Mass ⚠️ Conflicted

One meta-analysis of six small trials reported fat-mass loss without weight change, attributed to increased fat oxidation; a later meta-analysis covering largely the same trials found no effect on fat mass, fat-free mass or body mass index. Net reading: the fat-loss signal is not stable across analyses.

Magnitude: The positive analysis reported 2.53 kg less fat mass and 2.44 percentage points less body fat; the null analysis reported 0.57 kg less fat mass, which was not statistically distinguishable from zero.

Higher Total Testosterone

A three-week crossover trial in 43 CrossFit practitioners found a small rise in total testosterone at 2.5 and 5 grams daily, with no dose difference. A systematic review of testosterone-raising supplements rated betaine effective in male athletes on the strength of two studies. Untrained men and women are untested.

Magnitude: A 7.0 percent rise in total testosterone against 1.5 percent on placebo — within the normal reference range and of unknown clinical relevance.

Observational only. A two-year cohort of older adults with excess weight and metabolic risk factors linked higher dietary betaine intake to smaller declines in cognitive test scores; a separate cohort following women through the menopause transition found minimal effect. Net reading: unresolved.

Magnitude: Direction only — higher dietary intake tracks with a better two-year cognitive trajectory in one cohort and with no meaningful difference in another. The literature reports no outcome figure for supplemental betaine and cognition.

Speculative 🟨

Systemic Geroprotection Through Reduced Inflammation and Senescence

Basis is animal and mechanistic work only: in aged mice, betaine at exercise-equivalent concentrations improved motor coordination, muscle strength and spatial memory. Human inflammation trials pooled to date show no consistent effect.

Benefit-Modifying Factors

  • MTHFR C677T genotype: carriers of the T variant of MTHFR (the gene for the enzyme that activates folate for methyl transfer), whose folate route is slower, reached higher serum betaine after supplementation than CC homozygotes, though strength outcomes did not differ by genotype.

  • Baseline homocysteine: the absolute reduction scales with the starting concentration. Near-normal starters see little movement, while those above roughly 12 micromoles per liter see the largest falls. Betaine adds most where folate and vitamin B12 are already optimized and homocysteine remains high.

  • Baseline betaine status and diet: people eating little wheat bran, beets, spinach or shellfish start with lower plasma betaine and have more headroom. Habitual dietary intake of one to two grams daily already covers part of the supplemental dose range.

  • Baseline liver fat and liver enzymes: the liver signal appears only where there is liver injury to begin with. The dose-ranging trials enrolled people with ALT at or above 50 units per liter; those starting in the normal range have no measured benefit to gain.

  • Sex: only about one participant in five across the pooled performance trials was female. The one dedicated trial in women found greater fat-mass loss on betaine but no strength gain, so performance estimates remain anchored in men.

  • Pre-existing health conditions: a prediabetes trial found little metabolic effect despite a 16.5-fold rise in dimethylglycine, indicating the next enzyme in the chain is rate-limiting in that group. Fatty liver carries the clearest benefit signal.

  • Age: human trials concentrate in adults aged 18 to 40 and the pooled performance analysis capped enrolment at 60. The geroprotection data come from aged mice, so for adults in their sixties and beyond the benefit case rests on extrapolation.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Raised Total and LDL Cholesterol

The best-documented adverse effect and the main argument against high-dose use. Betaine at 4 grams daily or more raises total and LDL cholesterol (low-density lipoprotein, the particle that deposits cholesterol in artery walls) and, in some trials, triglycerides. The likely mechanism is increased liver export of fat as lipoprotein once methyl supply improves. A dedicated meta-analysis, a second independent meta-analysis and a pooled analysis of four placebo-controlled trials in healthy adults agree on direction; the effect appears within two weeks and is dose-dependent.

Magnitude: At 6 grams daily for six weeks, LDL cholesterol rose 0.36 millimoles per liter (about 14 mg/dL) and triglycerides 0.14 millimoles per liter. Pooled analyses report total cholesterol increases of 0.34 millimoles per liter (about 13 mg/dL) and LDL increases of about 10 mg/dL at doses of 4 grams daily or more.

Medium 🟥 🟥

Gastrointestinal Upset

Loose stools, nausea and abdominal discomfort are the most common complaints, and they follow directly from betaine’s osmotic behavior: unabsorbed material pulls water into the bowel. In the largest recent dose-ranging program in fatty liver disease, roughly 35 percent of participants reported mild, transient gastrointestinal symptoms at 1 to 8 grams daily. Symptoms are dose-related, appear early, and resolve on dose reduction or discontinuation; no serious gastrointestinal events were reported.

Magnitude: About 35 percent of participants across three dose-ranging trials reported mild, transient gastrointestinal symptoms. The published reports do not separate that rate by dose.

Low 🟥

Trimethylamine Load: Raised TMAO and Body Odor

Gut bacteria can convert betaine to trimethylamine, which the liver oxidizes to TMAO (trimethylamine N-oxide, a compound tied in observational work to cardiovascular risk); unoxidized trimethylamine causes a fishy body odor. In a crossover trial, TMAO rose but not significantly. Human data are sparse and uncontrolled.

Magnitude: Serum TMAO rose from 0.27 to 0.44 micrograms per milliliter in healthy active men, a change that did not reach statistical significance. Body odor frequency is not quantified in any trial.

Cerebral Edema (Brain Swelling) with Methionine Accumulation

Reported only in people with inherited cystathionine beta-synthase deficiency taking high-dose betaine, where methionine builds up instead of being cleared. At least seven published cases describe brain swelling that reversed on stopping betaine or lowering methionine. No case has been reported in people without the inherited enzyme fault.

Magnitude: Not quantified in available studies. Only case reports and a small case series exist — four new cases plus a review of the prior literature — so no incidence rate has been estimated, and every case occurred in a rare inherited metabolic disorder rather than in supplement users.

Speculative 🟨

Support of Tumor Growth Through Increased Methylation Capacity

Mechanistic concern only: methyl donors can silence tumor-suppressor genes and supply one-carbon units to dividing cells. A meta-analysis of dietary-intake cohorts points the opposite way, toward lower cancer incidence. No human supplementation outcome data exist.

Risk-Modifying Factors

  • Cystathionine beta-synthase deficiency: the one genotype in which high-dose betaine has caused documented harm. Methionine accumulates rather than clearing, and brain swelling has followed. In this group the marker that reveals the accumulation is plasma methionine, not homocysteine alone.

  • FMO3 variants: reduced-function carriers of FMO3 (the gene for the liver enzyme that converts fishy-smelling trimethylamine into odorless TMAO) are the group most likely to notice body odor on betaine, and the effect is dose-related.

  • Baseline lipid profile: the cholesterol rise is additive to whatever is already present. Anyone starting with LDL cholesterol above about 100 mg/dL, or with a strong family history of early heart disease, absorbs the increase from a worse position.

  • Sex: the lipid trials enrolled mostly men, or mixed groups without sex-stratified reporting, so whether the cholesterol response differs in women — particularly after menopause, when LDL rises anyway — is unmeasured.

  • Kidney function: betaine is cleared by metabolism rather than by the kidneys, with only about 4 percent excreted in urine, so impaired filtration does not cause accumulation. Reduced function does, however, raise baseline homocysteine and shift the starting point.

  • Age: older adults more often carry reduced kidney function, higher baseline homocysteine and higher cardiovascular risk, which magnifies both the potential upside and the cost of the cholesterol increase. The pooled performance trials were limited to ages 15 to 60.

Key Interactions & Contraindications

  • Homocysteine-lowering vitamins (folic acid, vitamin B12, vitamin B6): additive and intended; combined use lowers homocysteine further than either alone. Severity: monitor. Optimizing vitamin status first is the conventional sequence, since betaine adds little where the folate route is already saturated.

  • Choline and phosphatidylcholine supplements: additive on both fronts. Choline is converted to betaine, raising the effective dose, and both feed gut trimethylamine production. Severity: caution. Separating or reducing one keeps combined trimethylamine exposure down.

  • Creatine: overlapping osmolyte mechanism. The single trial combining them found no strength benefit beyond creatine alone. Severity: monitor for redundant spend rather than harm. No dose adjustment applies.

  • Statins (drugs that block the liver’s cholesterol production, such as atorvastatin) and ezetimibe: opposed in outcome, since betaine’s cholesterol rise partly offsets the drug. Severity: monitor. A lipid recheck 6 to 8 weeks after adding betaine detects the offset.

  • Folate antagonists (drugs that block the folate route to homocysteine clearance, such as methotrexate and trimethoprim): these leave betaine’s parallel route as the main one. Severity: monitor. Betaine does not interfere with the drug, but homocysteine may rise on the drug regardless.

  • Proton pump inhibitors (drugs that shut down stomach acid production, such as omeprazole): relevant only to betaine hydrochloride, a different product used to acidify the stomach, whose purpose these drugs neutralize. Severity: caution. Betaine anhydrous, the form studied here, is unaffected.

  • Over-the-counter niacin (nicotinic acid): consumes methyl groups during clearance and raises homocysteine, which betaine partly offsets. Severity: monitor. Both move the lipid panel in opposite directions, so changes need careful attribution.

  • NAD+ precursors (nicotinamide mononucleotide, nicotinamide riboside): NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy; its precursors consume methyl groups on clearance, which is why betaine is stacked with them. Severity: monitor. The pairing is untested for efficacy or lipid effect.

  • Methionine-restriction protocols and low-protein diets: directly opposed. Betaine raises methionine, the very metabolite such protocols aim to lower. Severity: caution. Betaine works against that goal.

Populations who should avoid Betaine:

  • Classical homocystinuria from cystathionine beta-synthase deficiency in which plasma methionine exceeds 1,000 micromoles per liter — the setting in which brain swelling has occurred.

  • People with existing atherosclerotic cardiovascular disease, or LDL cholesterol above 160 mg/dL, who are not monitoring lipids, at doses of 4 grams daily or more.

  • Diagnosed trimethylaminuria (fish-odor syndrome caused by FMO3 deficiency), in which any added trimethylamine load worsens symptoms.

  • Pregnancy and lactation, where evidence is limited to small pharmacokinetic studies in breastfeeding women and safety at supplemental doses is unestablished.

Risk Mitigation Strategies

  • Dose ceiling of 2 to 3 grams daily: the homocysteine effect is largely present below 4 grams daily while the cholesterol rise appears at or above it, so staying under the threshold avoids the principal adverse effect.

  • Lipid panel before starting and at 6 to 8 weeks: the LDL increase appears within two weeks and produces no symptoms. An 8-week recheck catches it before it accumulates cardiovascular risk.

  • Dose halved or stopped if LDL rises more than 10 mg/dL: the lipid effect is dose-dependent and reverses on withdrawal, so one measured response is enough to decide.

  • Divided doses taken with food: splitting 3 grams into two 1.5-gram doses with meals reduces the osmotic load that causes loose stools and nausea.

  • Folate, vitamin B12 and vitamin B6 corrected first: where homocysteine normalizes on vitamins alone, betaine adds a lipid cost for no further benefit.

  • Plasma methionine tracked above 6 grams daily: methionine accumulation is the step that precedes brain swelling in every reported case, and homocysteine alone does not reveal it.

  • Dose reduction at the first sign of body odor: trimethylamine production is dose-related and the odor resolves on reduction, signalling a shift of betaine into the gut-bacterial route.

Therapeutic Protocol

  • Standard supplemental dose: 2.5 grams daily is the dose used in most performance trials; 3 to 6 grams daily is the range used for homocysteine lowering. Protocols aiming at both typically settle at 2 to 3 grams.

  • Competing approaches: conventional practice treats raised homocysteine with folate and B vitamins first and reserves betaine for non-responders; longevity practice more often uses betaine from the outset. Neither approach has outcome trials behind it.

  • Liver-directed dose: trials in fatty liver disease used 2 to 8 grams daily for 12 to 24 weeks; the older histology trials used 20 grams daily, a dose the newer dose-ranging work suggests is unnecessary.

  • High-dose medical use: for inherited homocystinuria the prescribed regimen is 6 grams daily in two divided doses, titrated upward under specialist supervision with methionine monitoring.

  • Who popularized each approach: betaine’s sports use was developed largely through work funded by Danisco, its principal manufacturer, and carried forward by Jason Cholewa’s group; the longevity framing comes from Guang-Hui Liu’s laboratory in Beijing.

  • Best time of day: no circadian dependence has been demonstrated. Performance trials dosed 30 to 60 minutes before training or simply twice daily; chronic tissue loading rather than acute timing drives the effect.

  • Half-life and steady state: with an elimination half-life near 14 hours after a single dose, extending to roughly 41 hours on continuous dosing, plasma concentrations plateau after about a week.

  • Split versus single dose: split dosing is standard, at 1.25 to 3 grams twice daily. It smooths the osmotic load and matches the pattern used in the trials.

  • Genetic polymorphisms: MTHFR C677T T-allele carriers reach higher serum betaine on the same dose but did not perform differently. No dose adjustment by genotype is currently justified, and no other variant has been tested against betaine dosing.

  • Sex differences: the one dedicated trial in women used 2.5 grams daily and found greater fat loss but no strength gain, so dose extrapolation from male trials is not established.

  • Age considerations: trials stop at about 60 years. For older adults the conservative option is the lower end of the range with lipid monitoring, because baseline cardiovascular risk is higher.

  • Baseline biomarkers: response scales with starting homocysteine, so near-normal starters see little movement. Baseline lipids determine how much room exists for the cholesterol increase.

  • Pre-existing health conditions: raised liver enzymes with fatty liver is the condition with a measured response. Prediabetes trials found little metabolic effect despite a large rise in the downstream metabolite.

Discontinuation & Cycling

  • Intended duration: betaine is used continuously rather than in courses. Every measured benefit — homocysteine, strength, liver markers — depends on ongoing intake and reverts when supplementation stops.

  • Withdrawal effects: none reported. Serum betaine returned to baseline after a 21-day washout in a crossover trial, with no rebound in homocysteine above starting values.

  • Tapering: not applicable. The compound produces no receptor adaptation, and discontinuation was abrupt in every published trial without incident. Halving the dose is used only to manage loose stools.

  • Cycling: no efficacy rationale exists. There is no evidence of tolerance to the osmolyte or methyl-donor effects, so cycling offers nothing except a route to reverse an unwanted lipid change.

Sourcing and Quality

  • Naming on the label: betaine anhydrous, trimethylglycine and TMG (the abbreviation for trimethylglycine) all denote the same compound. Betaine hydrochloride is a different product, used to acidify the stomach, and is not the form used in efficacy trials.

  • Source material: almost all supplemental betaine is recovered from sugar-beet molasses as a byproduct of sugar refining, which makes it inexpensive and uniform in composition. Synthetic material from betaine aldehyde oxidation is chemically identical.

  • Third-party testing: verification marks that indicate independent identity and purity testing include USP (United States Pharmacopeia, the standards body that sets and verifies supplement quality specifications), NSF certification, and Informed Sport certification for competitors subject to drug testing.

  • Formulation: powder is the least expensive form and dissolves freely, while capsules at 500 to 1,000 milligrams require six or more units to reach the trial dose. Betaine is hygroscopic, so open powders clump.

  • Brands and pharmacies: commodity-grade betaine anhydrous is sold by NOW Foods, BulkSupplements, Thorne and Life Extension, among others. The prescription betaine anhydrous product is dispensed by specialty pharmacies only for inherited metabolic disease.

Practical Considerations

  • Time to effect: homocysteine falls measurably within 2 to 6 weeks; the lipid increase appears within 2 weeks; strength effects required at least 7 days of supplementation and were measured over 2 to 6 weeks of training.

  • Common pitfalls: buying betaine hydrochloride instead of anhydrous; dosing at 6 grams or more on the assumption that more methyl donation is better, which is exactly where the lipid cost appears; and never measuring lipids at all.

  • Regulatory status: betaine anhydrous is sold as a dietary supplement and holds generally recognized as safe (GRAS) status as a food ingredient. The same compound is also approved by the US Food and Drug Administration as a prescription drug for inherited homocystinuria.

  • Cost: bulk betaine anhydrous powder costs a few cents per gram, so a year at 3 grams daily is among the least expensive interventions covered in this review. Capsules cost several times more per gram.

  • Payer incentives: the prescription product costs orders of magnitude more than the identical over-the-counter compound, giving insurers and national health systems a direct financial reason to prefer the supplement route — a structural bias that shapes coverage decisions rather than trial evidence.

Interaction with Foundational Habits

  • Sleep: no direct interaction. Betaine is not stimulatory, and no trial has reported insomnia or sedation. The indirect route runs through methylation, since methyl groups are consumed in melatonin synthesis, making adequate methyl supply a background requirement rather than a sleep intervention. Evening dosing is unproblematic.

  • Nutrition: direct and substantial. Wheat bran, wheat germ, beets, spinach, quinoa and shellfish supply one to two grams daily, so a diet rich in them meaningfully reduces the supplemental dose needed. Choline-rich foods such as eggs and liver raise betaine indirectly. Taking betaine with a meal reduces loose stools.

  • Exercise: potentiating, and the interaction runs both ways. Repeated endurance training itself raises betaine, chiefly through kidney synthesis. Supplementation improves lower-body maximal strength, with the largest effects in high-volume, metabolically stressful protocols, and does nothing measurable for sprint power or upper-body strength. Trials dosed 30 to 60 minutes before training.

  • Stress management: blunting for physical stress, unmeasured for psychological stress. Betaine’s cellular role is osmotic and heat protection. A crossover trial in young athletes found lower post-exercise cortisol on 2.5 grams daily, while a larger CrossFit trial found none; no trial has tested a psychological stressor.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes both the target and the tripwire. The target is plasma homocysteine, which determines whether betaine has anything to move; the tripwire is a full lipid panel, because the cholesterol increase is the one adverse effect that is both common and silent. Liver enzymes and estimated glomerular filtration rate (eGFR, a calculated measure of how well the kidneys filter blood) complete the picture, since liver and kidney both concentrate betaine. Vitamin B12 and folate belong in the same draw, because correcting either deficiency comes first.

Ongoing testing follows the biology rather than the calendar. A lipid recheck at 6 to 8 weeks falls after the effect has fully appeared but before it matters, and homocysteine is repeated at 12 weeks. If both are stable the cadence drops to annual, returning to 8 weeks after any dose change.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Homocysteine 5–8 µmol/L The target betaine acts on; shows whether there is room to move Conventional labs flag only above 15 µmol/L. Fast 10–12 hours and separate plasma promptly, or values drift upward
LDL cholesterol <100 mg/dL; <70 mg/dL with existing cardiovascular disease The principal adverse effect at doses of 4 g daily or more Conventional range accepts <130 mg/dL. Pair with apoB (apolipoprotein B, a direct count of artery-damaging particles) where available
Total cholesterol and triglycerides Total <180 mg/dL; triglycerides <100 mg/dL Both rose in the pooled betaine trials Conventional cut-offs are <200 and <150 mg/dL. Requires a 12-hour fast for triglycerides; draw at the same time of day on repeat
Alanine aminotransferase (ALT) <25 U/L in men, <20 U/L in women Marks liver injury and is the endpoint that improved in the dose-ranging trials Conventional upper limits near 40 U/L are too permissive. Pair with AST (aspartate aminotransferase, a second liver enzyme)
Plasma methionine 15–35 µmol/L Rises as homocysteine falls; accumulation is the step preceding brain swelling in the reported cases Needed only above 6 g daily or in inherited metabolic disease. Fasting sample
eGFR >90 mL/min/1.73 m² The kidney is where exercise-driven betaine synthesis occurs and where betaine concentrates most Conventional threshold for concern is <60. Creatinine-based estimates are distorted by high muscle mass; cystatin C is the better estimate in trained individuals
Vitamin B12 and folate B12 >500 pg/mL; folate >10 ng/mL Shows whether the folate route is already saturated before betaine is added Conventional B12 range starts near 200 pg/mL. Supplementing betaine over low B12 masks the deficiency’s homocysteine signal
TMAO No established target; track the change from the individual’s own baseline Betaine feeds the gut pathway that produces it Assays vary widely between laboratories, so only within-laboratory comparisons are meaningful. Fasting sample, and avoid fish for 24 hours beforehand

Qualitative markers worth tracking alongside the laboratory panel:

  • Training performance: session volume at a fixed load in high-repetition lower-body work is the most sensitive qualitative signal, and the one that matches where the trial evidence sits.

  • Digestive tolerance: stool consistency during the first two weeks indicates whether the dose exceeds absorptive capacity.

  • Body odor: a new fishy note signals trimethylamine overflow into the gut-bacterial route.

  • Energy and recovery: subjective, unvalidated, and not separable from training effects — useful only as a prompt to look at the objective markers.

Emerging Research

  • Controlled test of low-dose betaine in fatty liver disease: NCT07276204 is a placebo-controlled phase 2 trial of 70 participants with metabolic dysfunction-associated steatohepatitis (MASH, the inflammatory form of fatty liver disease), starting in 2026. It is the first controlled test of the low-dose range.

  • First controlled test in a neurological condition: NCT06308367 is a phase 2 trial of 30 participants with refractory syringomyelia (a fluid-filled cavity in the spinal cord) at the Beijing hospital behind the exercise-mimetic work, testing betaine’s osmolyte role against a spinal-cord function score.

  • Replication of the exercise-mimetic finding: the 2025 report by Geng et al. rests on 13 young men plus aged mice. Whether betaine reproduces the protective effect in older humans at achievable doses is the single question that would most change the picture.

  • Whether the lipid cost holds at longevity-relevant doses: Ashtary-Larky et al., 2022 place the threshold at 4 grams daily from subgroup analysis rather than a dedicated dose-response trial. A trial designed to test that threshold could remove the main objection to betaine or confirm it.

  • Dietary betaine and cognitive trajectory: the cohort analysis by Vázquez-Lorente et al., 2026 links intake to two-year cognitive change in older adults, while Cowan-Pyle et al., 2024 find little across the menopause transition. Neither tests supplementation.

  • Trimethylamine load as a counterweight: whether chronic betaine meaningfully raises TMAO is unresolved, and the one crossover measurement moved in the unfavorable direction without reaching significance.

Conclusion

Betaine is an inexpensive, food-derived compound with one clear job — handing out the small chemical tags called methyl groups — and one clear consequence of doing that job well. It lowers the blood marker homocysteine consistently, and at the same doses that achieve this it raises total and harmful cholesterol. That trade-off, rather than any single benefit, sits at the center of the betaine case.

Where the evidence is strongest, it is narrow. Lower-body strength improves across many small training studies. Liver fat and markers of liver injury shift in people who already have fatty liver. Fat loss and thinking skills each show a signal in one analysis and none in another; the testosterone rise rests on two small trials in men. The longevity claim that drew recent attention rests on aged mice and a single small human profiling study, not on outcomes in older people.

The evidence base itself is uneven in a way worth naming. Much of the early nutrition and sports work was funded by the principal manufacturer, and the most accessible practitioner writing on betaine is published by companies that sell it. The independent pooled analyses are small, overlap heavily in the trials they draw on, and are concentrated in young men.

What emerges is a compound whose short-term effects are real, measurable and modest, whose main cost shows up in the same blood draw that tracks its main benefit, and whose longevity case remains a hypothesis under test.

Top - Benefits - Risks - Protocol